Michael Schmertzler
Independent Chairman of the BoardMr. Michael Schmertzler is Director of AgNovos Healthcare, LLC. He serves as Independent Chairman of the Board of PTC Therapeutics, Inc. since 2004 and has served as a Director since August 2001. He serves as Independent Director at Hamilton Lane Incorporated since July 22, 2026. He joined the firm on July 22, 2025. He has been a Visiting Professor at Yale NUS since 2018 and an Adjunct Professor and Lecturer in Economics at Yale University since 2008. He has been an Independent Director of Novirio Pharmaceuticals Ltd. since April 2001 and a Director of eMed Technologies Corp. since March 1992. He serves as Chairman and a Director of Berryville Holdings, as Chairman and a Director of Dispel, LLC, as Executive Chairman of SHY Therapeutics and as a Director of AgNovos. He also serves as Chair Emeritus of NOLS Wilderness Medicine, as a Director of Monogram Energy, Inc. and as a Charter Trustee of Phillips Academy Andover. He serves at American Express Company and Morgan Stanley. He served as a post-bankruptcy independent director of Lehman Commercial Paper, Inc. from 2012 to 2020. He served as a Managing Director at Credit Suisse First Boston Equity Partners, L.P. from 1997 to 2014. He served as Independent Director at Cytokinetics, Incorporated, where he was employed from April 2003 to November 1, 2010. He served as Managing Director of Aries Advisors LLC, a sub-advisor to Credit Suisse First Boston Equity Partners LP, since 2001. He served as Managing Director of CSFB Private Equity from 1997 to February 2001 and also served as its Co-Head of U.S. and Canada. He served as the Co-Head of United States and Canadian Private Equity of Credit Suisse First Boston from 1997 to 2001. From October 1993 to November 1997, he served as the President of the Morgan Stanley Leveraged Capital Funds and Morgan Stanley Leveraged Equity Fund II and a Managing Director of Morgan Stanley's mergers and acquisitions and corporate finance departments. He served as Managing Director of MS Partners Inc. from 1992 to 1994, a general partner of MSX Public Life Sciences Fund. He is Co-Founder of Kolltan Pharmaceuticals, Inc. and also served as its Chief Executive Officer, Chief Scientist and Director. He co-founded eMed Technologies Corporation in March 1992. He served as Managing Director and Co-Head of U.S. & Canada of Credit Suisse Private Equity, LLC, where he focused on U.S. and Canadian activities. He also served as Co-Head at Credit Suisse First Boston's Private Equity Partners, LP and Credit Suisse First Boston Equity Partners (Bermuda), LP. He served as Managing Director and Chief Financial Officer of Lehman Brothers Kuhn Loeb. He was a Director of Idenix Pharmaceuticals, Inc., Marquis Tech Holdings, Inc., Merge Healthcare North America and Zyomyx, Inc. He joined Merge Healthcare North America in March 1992. He received a B.A. in Biochemistry, City Planning, History & Molecular Biology from Yale College from 1993 to 1997 and an M.B.A. from the Harvard Business School. Mr. Schmertzler has B.A. in Molecular Biology, History, Biochemistry, City Planning from Yale College in 1997. Mr. Schmertzler has M.B.A. from Harvard Business School.
Positions
- Company NamePTC Therapeutics, Inc.Stock CodePTCTPositionIndependent Chairman of the Board
